ERBB2 and breast carcinoma: Based on the successful history of anti-HER2 therapy with trastuzumab in HER2-overexpressing and/or amplified breast cancer, several authors focused their interest on HER2 aberrations in advanced NSCLC (aNSCLC) [16,17].